Trial reportLipids in health and disease2020
A comprehensive metabolic profiling of the metabolically healthy obesity phenotype.
Trial report in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01034436 (Fatty Acid Quality and Overweight), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fatty Acid Quality and Overweight
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Recruiting and Engaging Women of Reproductive Age with Obesity: Insights from A Mixed-Methods Study within A Trial.International journal of environmental research and public health · 2022Trial
- Acute aerobic exercise reveals that FAHFAs distinguish the metabolomes of overweight and normal-weight runners.JCI insight · 2022Trial
- Weight Loss Measurements Under the Microscope: How Type and Baseline Definition Shape Clinical Response After Metabolic-Bariatric Surgery - A 2-Year Follow-up Analysis of 17,568 Patients.Obesity surgery · 2026Article
- Transcutaneous allicin oleogel restores energy homeostasis for obesity treatment.Acta pharmacologica Sinica · 2026Article
- A six-metabolite signature characterizes metabolically unhealthy obesity and reveals hidden metabolic risk within metabolically healthy obesity.Frontiers in endocrinology · 2026Article
- Dietary Modulation of Metabolic Health: From Bioactive Compounds to Personalized Nutrition.Metabolites · 2025Review
- Amino Acid Associations in Healthy and Unhealthy Obesity.The Journal of nutrition · 2025Article
- Metabolome alterations in pediatric metabolically unhealthy obesity are primarily linked to abnormal glucose homeostasis.Scientific reports · 2025Article
- Article
- Anti-obesity peptides from food: Production, evaluation, sources, and commercialization.Comprehensive reviews in food science and food safety · 2025Review
- Lipids as key biomarkers in unravelling the pathophysiology of obesity-related metabolic dysregulation.Heliyon · 2025Article
- Beyond Nutritional Treatment: Effects of Fitwalking on Physical Capacity and Intestinal Barrier Integrity in BMI-Stratified IBS Patients.Nutrients · 2024Article
- Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A personalized probabilistic approach to ovarian cancer diagnostics.Gynecologic oncology · 2024Article
- Heterogeneously elevated branched-chain/aromatic amino acids among new-onset type-2 diabetes mellitus patients are potentially skewed diabetes predictors.World journal of diabetes · 2024Article
- Obesity and Dyslipidemia: A Review of Current Evidence.Current obesity reports · 2023Review
- Clinical Blood Metabogram: Application to Overweight and Obese Patients.Metabolites · 2023Article
- Cardiovascular risk of metabolically healthy obesity in two european populations: Prevention potential from a metabolomic study.Cardiovascular diabetology · 2023Article
- Metabolically Healthy Obesity: Are Interventions Useful?Current obesity reports · 2023Review
- Dietary Intakes and Eating Behavior between Metabolically Healthy and Unhealthy Obesity Phenotypes in Asian Children and Adolescents.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as "metabolically healthy obese" (MHO). In contrast to metabolically unhealthy obese (MUO), the MHO phenotype has a favorable risk profile. Despite this, the MHO phenotype is still sub-optimally characterized with respect to a comprehensive risk assessment. Our aim was to increase the understanding of metabolic alterations associated with healthy and unhealthy obesity.
methodsIn this cross-sectional study, men and women (18-70 years) with obesity (body mass index (BMI) ≥ 30 kg/m
resultsThe concentrations of very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low density lipoprotein (LDL) subclasses were overall significantly higher, and high density lipoprotein (HDL) subclasses lower in MUO compared with MHO. VLDL and IDL subclasses were significantly lower and HDL subclasses were higher in NW compared with MHO. The concentration of isoleucine, leucine and valine was significantly higher in MUO compared with MHO, and the concentration phenylalanine was lower in NW subjects compared with MHO. The fatty acid profile in MHO was overall more favorable compared with MUO.
conclusionsComprehensive metabolic profiling supports that MHO subjects have intermediate-stage cardiovascular disease risk marker profile compared with NW and MUO subjects. CLINICAL TRIAL REGISTRATION NUMBER: NCT01034436, Fatty acid quality and overweight (FO-study).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.